IN-VITRO AND IN-VIVO ACTIVITIES OF THE BENZOXAZINORIFAMYCIN KRM-1648 AGAINST MYCOBACTERIUM-TUBERCULOSIS

被引:65
|
作者
HIRATA, T
SAITO, H
TOMIOKA, H
SATO, K
JIDOI, J
HOSOE, K
HIDAKA, T
机构
[1] SHIMANE MED UNIV, DEPT MICROBIOL & IMMUNOL, IZUMO, SHIMANE 693, JAPAN
[2] SHIMANE MED UNIV, DEPT DERMATOL, IZUMO, SHIMANE 693, JAPAN
[3] NATL INST LEPROSY RES, TOKYO 189, JAPAN
[4] KANEKA CORP, BIOCHEM RES LABS, TAKASAGO, HYOGO 676, JAPAN
关键词
D O I
10.1128/AAC.39.10.2295
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro and in vivo activities of a new benzoxazinorifamycin, KRM-1648 (KRM), against Mycobacterium tuberculosis were studied. The MIC at which 50% of the isolates are inhibited (MIC(50)) and the MIC(90) of KRM for 30 fresh isolates of M. tuberculosis measured by the BACTEC 460 TB System,were 0.016 and 2 mu g/ml, respectively. These values were much lower than those for rifampin (RMP), which were 4 and >128 mu g/ml, respectively, and considerably lower than those for rifabutin (RBT), which were 0.125 and 8 mu g/ml, respectively. A correlational analysis of the MICs of these drugs for the clinical isolates revealed the presence of cross-resistance of the organisms to KRM and either RMP or RBT although the MICs of KRM were distributed over a much lower range than were those of the other two drugs. KRM and RMP at concentrations of 1 to 10 mu g/ml almost completely inhibited the bacterial growth of RMP-sensitive strains (H,,Rv, Kurono, and Fujii) of M. tuberculosis phagocytosed in macrophage-derived J774.1 cells. KRM was more active than RMP in inhibiting the growth of the RMP-resistant (MIC = 8 mu g/ml) Kurata strain but failed to show such an effect against the RMP-resistant (MIC > 128 mu g/ml) Watanabe strain. When KRM was given to M. tuberculosis-infected mice at dosages of 5 to 20 mg/kg of body weight by gavage, once daily six times per week from day 1 after infection, it was much more efficacious than RMP against infections induced in mice by the RMP-sensitive Kurono strain, as measured by a reduction of rates of mortality, a reduction of the frequency and extent of gross lung lesions, histopathological changes in lung tissues, and a decrease in the bacterial loads in the lungs and spleens of infected mice. KRM also displayed significant therapeutic efficacy against infection induced by the RMP-resistant Kurata strain, while neither KRM nor RMP was efficacious against infection by the RMP-resistant Watanabe strain. In the case of infection with the Kurono strain, the efficacy of the drugs in prolonging the time of survival was in the order KRM, RBT, RMP. KRM was much more efficacious than RMP, when given at 1- to 4-week intervals. These findings suggest that KRM may be useful for the clinical treatment of tuberculosis contracted through RMP-sensitive strains, even when it is administered at long intervals.
引用
收藏
页码:2295 / 2303
页数:9
相关论文
共 50 条
  • [21] CHEMOTHERAPEUTIC EFFICACY OF A NEWLY SYNTHESIZED BENZOXAZINORIFAMYCIN, KRM-1648, AGAINST MYCOBACTERIUM-AVIUM COMPLEX INFECTION INDUCED IN MICE
    TOMIOKA, H
    SAITO, H
    SATO, K
    YAMANE, T
    YAMASHITA, K
    HOSOE, K
    FUJII, K
    HIDAKA, T
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (02) : 387 - 393
  • [22] Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis
    Yang, B
    Koga, H
    Ohno, H
    Ogawa, K
    Fukuda, M
    Hirakata, Y
    Maesaki, S
    Tomono, K
    Tashiro, T
    Kohno, S
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (05) : 621 - 628
  • [23] Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice
    Tomioka, H
    Sato, K
    Shimizu, T
    Sano, C
    Akaki, T
    Saito, H
    Fujii, K
    Hidaka, T
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) : 357 - 362
  • [24] Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, in SCID mouse model for disseminated Mycobacterium avium complex infection
    Emori, M
    Tomioka, H
    Sato, K
    Saito, H
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 10 (01) : 59 - 65
  • [25] THERAPEUTIC EFFICACY OF BENZOXAZINORIFAMYCIN, KRM-1648, IN COMBINATION WITH OTHER ANTIMICROBIALS AGAINST MYCOBACTERIUM-LEPRAE INFECTION-INDUCED IN NUDE-MICE
    SAITO, H
    TOMIOKA, H
    SATO, K
    DEKIO, S
    INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES, 1994, 62 (01) : 43 - 47
  • [26] CHEMOTHERAPEUTIC ACTIVITY OF CLOFAZIMINE AND ITS ANALOGS AGAINST MYCOBACTERIUM-TUBERCULOSIS - IN-VITRO, INTRACELLULAR, AND IN-VIVO STUDIES
    JAGANNATH, C
    REDDY, MV
    KAILASAM, S
    OSULLIVAN, JF
    GANGADHARAM, PRJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (04) : 1083 - 1086
  • [27] Antimicrobial activities of clarithromycin, KRM-1648, and levofloxacin against Mycobacterium tuberculosis and M-avium complex grown in a medium or inside macrophages
    Sato, K
    Akaki, T
    Tomioka, H
    12TH MEDITERRANEAN CONGRESS OF CHEMOTHERAPY, 2000, : 359 - 362
  • [28] Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations
    Moghazeh, SL
    Pan, X
    Arain, T
    Stover, CK
    Musser, JM
    Kreiswirth, BN
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) : 2655 - 2657
  • [29] Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice
    Shimizu, T
    Tomioka, H
    Sato, K
    Sano, C
    Akaki, T
    Dekio, S
    Yamada, Y
    Kamei, T
    Shibata, H
    Higashi, N
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) : 514 - 519
  • [30] INHIBITORY AND BACTERICIDAL ACTIVITIES OF LEVOFLOXACIN AGAINST MYCOBACTERIUM-TUBERCULOSIS IN-VITRO AND IN HUMAN MACROPHAGES
    MOR, N
    VANDERKOLK, J
    HEIFETS, L
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) : 1161 - 1164